semaglutide ckd trial in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical Semaglutide could be 'practice changing'

The general principle that applies to the whole class still holds: start low, escalate slowly, and let tolerability guide the pace

Always remember to consult your healthcare provider for personalized advice and treatment plans

Its important to note that the negative effects of being overweight on cognitive performance seem to begin before reaching very old age, as indicated by the findings related to mean-level cognitive performance and only one ability showing differences in performance changes over time

Gastrointestinal side effects like mild nausea, occasional bloating, or changes in bowel habits are common but usually manageable

Describing the extreme side effects she experienced on the lowest dose, Bialik continued, Explosive, uncontrollable diarrhea